AI in Precision Medicine Market – Global Forecast To 2030
정밀의학 시장의 AI – 응용 (창약, 스크리닝, 진단, 계층화, 병기 분류, 예후, 치료법 선택, 모니터링, 위험 관리), 적응증 (암, CNS, CVS), 도구 (ML, NLP), 최종 사용자 – 2030년까지의 세계 예측
AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030
| 조사회사 | MarketsandMarkets |
| 출판년월 | 2024년12월 |
| 페이지 수 | 403 |
| 도표 수 | 385 |
| 라이센스 | Single User License |
| 가격 | USD 4,950 |
| 구성 | 영문조사보고서 |
Report Overview
The AI in precision medicine market is projected to reach USD 3.92 billion by 2030 from USD 0.78 billion in 2024, at a CAGR of 30.7% from 2024 to 2030.
정밀의학 시장의 AI는 2024년부터 2030년까지 30.7%의 CAGR로 성장했으며, 2024년 7억 8,000만 달러에서 2030년까지 39억 2,000만 달러에 이를 것으로 예측됩니다.
The market for AI in precision medicine is propelled by the enhanced diagnostics as well as predictive analytics. Wearable devices monitor patient’s imaging and other related parameters and search for signs of disease, long before it shows itself, or the outcomes of treatments. Additionally, the movement towards cheaper healthcare provision is also the other factor. AI increases the productivity of conventional diagnosis and treatment procedures; thus, it makes precision medicine cheap and widely applicable. On the contrary, factors such as costs associated with implementation, inadequate access to high-quality data and issues with data security and privacy present challenges. Furthermore, the intricate nature of incorporating AI into already existing healthcare processes including regulatory requirements may also slow down its uptake.
“Natural language processing (NLP) had the fastest growth rate in the AI in precision medicine market during the forecast period, by tools.”
Natural Language Processing (NLP) is anticipated to register the highest growth rate within the AI in precision medicine market as a result of its efficiency in deriving meaning from adequate unstructured medical data which consist of clinical notes, research works, and patient records. NLP helps to integrate unstructured data with structured data helps to get a better view of patient’s history and suggestions regarding customizing treatment are improved. For instance, Tempus utilizes NLP techniques in fresh oncology treatment plans to find trends in the use of electronic health records. Furthermore, NLP-based applications are used to provide concise reports and help in making decisions very fast by shifting through a lot of scientific data and literature which hastens the process of drug invention and the diagnosis of diseases. The growing implementation of EHR systems alongside the rising need for precision medicine integrated solutions stimulates the market for NLP technology. Its applicability in dealing with different healthcare data and promise of better results makes it a game changer in the market.
“By end user, the healthcare providers to account for largest market share in 2023.”
By end user, AI in precision medicine market is bifurcated into healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others. The healthcare providers accounted for the largest share of the market for AI in precision medicine owing to the fact that they are the foremost practitioners of the AI tools used to enhance diagnosis, treatment planning and patient outcome. Hospitals and clinics employ AI platforms for patient data analysis, therapeutic mapping, and improving the quality of decision making. The current rampant deployment of the AI technology in the fields of medical imaging, genomics and custom care provision has made it possible for providers to give customized therapies in a quick and effective manner. In addition, the rising expenditure on AI solutions and the increasing demand for efficient and high quality healthcare systems are two factors that facilitate penetration of the market by healthcare providers.
“Asia Pacific is estimated to register the highest CAGR over the forecast period.”
The AI in precision medicine market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific’s AI in precision medicine market is projected to register highest CAGR during the forecast period due to enhanced allocation of resources towards healthcare infrastructure facilities, promotion of adoption of AI technology, and growing initiatives in genomic research. Countries like China, Japan and India are turning towards advanced technologies like Artificial Intelligence to transform the health care systems in these nations, due to government and private organization efforts. At the same time, the aging population creates a high demand for precision therapeutics, especially for oncology and chronic illness management, which also promotes growth in this region. In addition, an influx of both global and local companies specializing in the technology in the region, stimulates speed of innovation and use of the technology.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: Managers (40%), Directors (35%), and Others (25%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)
List of Companies Profiled in the Report:
o NVIDIA Corporation (US)
o Google, Inc. (US)
o Microsoft (US)
o IBM (US)
o Illumina, Inc. (US)
o Exscientia (UK)
o Insilico Medicine (US)
o GE Healthcare (US)
o Tempus AI, Inc. (US)
o Siemens Healthineers AG (Germany)
o BioXcel Therapeutics, Inc. (US)
o BenevolentAI (UK)
o PathAI, Inc. (US)
o Guardant Health (US)
o GRAIL, Inc. (US)
o FOUNDATION MEDICINE, INC. (US)
o FLATIRON HEALTH (US)
o Proscia Inc. (US)
o DEEP GENOMICS. (Canada)
o Verge Genomics (US)
o Predictive Oncology (US)
o Paige AI, Inc. (US)
o Densitas Inc. (Canada)
o Zephyr AI (US)
o Iktos (France)
Research Coverage:
This research report categorizes the AI in precision medicine market by application (drug discovery & development, diagnostics & screening, and therapeutics), therapeutic area (oncology, rare diseases, infectious diseases, neurology, cardiology, haematology, and others), component (hardware, software, and services), tools (machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition), and others), deployment (cloud-based model, on-premise model, and hybrid model), end user (healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in precision medicine market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in precision medicine market. Competitive analysis of upcoming startups in the AI in precision medicine market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in precision medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers: (Rising Demand for Personalized Healthcare), restraints (Limited access to high-quality data), opportunities (Expanding genomic research), and challenges (Regulatory and ethical complexities) influencing the growth of the AI in precision medicine market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in precision medicine market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the AI in precision medicine market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in precision medicine market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as NVIDIA Corporation (US), Google, Inc. (US), Microsoft (US), IBM (US), Illumina, Inc. (US), Exscientia (UK), etc. among others in AI in precision medicine market.
Table of Contents
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 STUDY SCOPE 33
1.3.1 MARKETS COVERED & REGIONAL SCOPE 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 36
1.5 STAKEHOLDERS 36
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
2.1.2.1 Key data from primary sources 42
2.2 MARKET SIZE ESTIMATION 44
2.3 MARKET SHARE ESTIMATION 47
2.4 DATA TRIANGULATION 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 LIMITATIONS 49
2.6.1 METHODOLOGY-RELATED LIMITATIONS 49
2.6.2 SCOPE-RELATED LIMITATIONS 49
2.7 RISK ASSESSMENT 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 57
4.1 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OVERVIEW 57
4.2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION 58
4.3 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER & REGION 59
4.4 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHIC SNAPSHOT 60
4.5 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEVELOPED VS. EMERGING MARKETS 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
5.3 MARKET DYNAMICS 62
5.3.1 DRIVERS 62
5.3.1.1 Increase in investments in R&D and rise in demand for personalized medication 62
5.3.1.2 Advancements in genomic research and data availability 64
5.3.1.3 Growth in cross-industry collaborations and partnerships 64
5.3.1.4 Role of regulatory landscape in driving AI adoption in healthcare 66
5.3.2 RESTRAINTS 68
5.3.2.1 Increase in data breach concerns 68
5.3.2.2 High cost of implementation of precision medicine solutions 70
5.3.2.3 Accuracy challenges in AI adoption for healthcare 71
5.3.3 OPPORTUNITIES 71
5.3.3.1 Role of predictive analytics in advancing AI for healthcare 71
5.3.3.2 Leveraging research pipelines and new drug development for AI in healthcare 72
5.3.4 CHALLENGES 73
5.3.4.1 Impact of fairness and bias on AI in healthcare 73
5.3.4.2 Interoperability challenges due to complexity of AI solutions 74
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 74
5.5 INDUSTRY TRENDS 75
5.5.1 AI’S GROWING ROLE IN PATIENT-SPECIFIC DATA INTEGRATION AND ANALYSIS 75
5.5.2 ADVANCEMENTS IN AI-POWERED PREDICTIVE ANALYTICS FOR TREATMENT OPTIMIZATION 76
5.6 ECOSYSTEM ANALYSIS 76
5.7 VALUE CHAIN ANALYSIS 79
5.8 TECHNOLOGY ANALYSIS 80
5.8.1 KEY TECHNOLOGIES 80
5.8.1.1 Predictive analytics 80
5.8.1.2 Neural networks 81
5.8.1.3 Knowledge graphs 81
5.8.1.4 Cell and gene therapies 81
5.8.1.5 AI-driven single-cell analysis 82
5.8.2 COMPLEMENTARY TECHNOLOGY 82
5.8.2.1 High-performance computing (HPC) 82
5.8.2.2 Next-generation sequencing 82
5.8.2.3 Real-world evidence/Real-world data 83
5.8.2.4 EHR Integration 83
5.8.2.5 Digital health platforms 84
5.8.3 ADJACENT TECHNOLOGIES 84
5.8.3.1 Cloud computing 84
5.8.3.2 Blockchain technology 84
5.8.3.3 Internet of Things (IoT) and wearables 85
5.8.3.4 Robotics and automation 85
5.8.3.5 3D printing for personalized implants and devices 85
5.9 REGULATORY ANALYSIS 86
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.9.2 REGULATORY SCENARIO 89
5.10 PRICING ANALYSIS 93
5.10.1 INDICATIVE PRICING FOR KEY PLAYERS 93
5.10.2 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION 94
5.11 PORTER’S FIVE FORCES ANALYSIS 95
5.11.1 THREAT OF NEW ENTRANTS 96
5.11.2 THREAT OF SUBSTITUTES 96
5.11.3 BARGAINING POWER OF SUPPLIERS 96
5.11.4 BARGAINING POWER OF BUYERS 97
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 97
5.12 PATENT ANALYSIS 97
5.12.1 PATENT PUBLICATION TRENDS 97
5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE 98
5.12.3 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET 99
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 102
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
5.13.2 KEY BUYING CRITERIA 103
5.14 END-USER ANALYSIS 104
5.14.1 UNMET NEEDS 104
5.14.2 END-USER EXPECTATIONS 105
5.15 KEY CONFERENCES & EVENTS 106
5.16 CASE STUDY ANALYSIS 107
5.16.1 SANOFI LEVERAGED AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE 107
5.16.2 IBM’S AI-DRIVEN SOLUTION IMPROVED CLINICAL TRIAL ENROLLMENT AT MAYO CLINIC BY ENHANCING PATIENT MATCHING 108
5.16.3 ENHANCING PATIENT IDENTIFICATION FOR RARE ONCOLOGY BIOMARKERS THROUGH GENOMIC TESTING AND STRATEGIC COLLABORATION 108
5.17 INVESTMENT AND FUNDING SCENARIO 109
5.18 BUSINESS MODELS 109
5.19 IMPACT OF AI/GEN AI IN PRECISION MEDICINE MARKET 111
5.19.1 KEY USE CASES 112
5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 112
5.19.2.1 Enhancing patient outcomes with AI-driven predictive analytics at Johns Hopkins Hospital 112
5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 113
5.19.3.1 AI in drug discovery market 113
5.19.3.2 Genomics market 113
5.19.3.3 Artificial intelligence market 114
5.19.3.4 Pharmacogenomics market 114
5.19.4 USER READINESS AND IMPACT ASSESSMENT 114
5.19.4.1 User readiness 114
5.19.4.1.1 Healthcare providers 114
5.19.4.1.2 Pharmaceutical & biotechnology companies 114
6 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION 115
6.1 INTRODUCTION 116
6.2 DRUG DISCOVERY & DEVELOPMENT 116
6.2.1 DRUG DISCOVERY 117
6.2.2 UNDERSTANDING DISEASES 117
6.2.2.1 Rise in data mining to link targets to diseases 117
6.2.3 DRUG REPURPOSING 118
6.2.3.1 Use of graphs for targeted approach to reduce timelines and costs 118
6.2.4 DE NOVO DRUG DESIGN 119
6.2.4.1 Availability of large-scale biomedical datasets and urgent demand for novel treatments for complex diseases 119
6.2.5 DRUG OPTIMIZATION 120
6.2.5.1 Need to process extensive data on molecular properties, target interactions, and clinical outcomes 120
6.2.6 SAFETY & TOXICITY 121
6.2.6.1 Building generalizable model for toxicity and off-target effect prediction 121
6.2.7 CLINICAL DEVELOPMENT 122
6.2.7.1 Designing and conducting clinical trials for personalized dosing, targeted therapies 122
6.3 DIAGNOSTICS & SCREENING 124
6.3.1 RISK ASSESSMENT & PATIENT STRATIFICATION 124
6.3.1.1 Leveraging AI to personalize treatment plan 124
6.3.2 DISEASE SCREENING 125
6.3.2.1 Leveraging machine learning to peruse and resolve complex patient data 125
6.3.3 DISEASE DIAGNOSIS 126
6.3.3.1 Identifying biomarkers for precise treatment 126
6.3.4 DISEASE PROGRESSION, STAGING, AND PROGNOSIS 127
6.3.4.1 Using AI to track disease conditions 127
6.4 THERAPEUTICS 128
6.4.1 THERAPY SELECTION & PLANNING 129
6.4.1.1 Leveraging generative models to predict and design suitable treatment 129
6.4.2 THERAPY MONITORING 130
6.4.2.1 Need to effectively track safety and efficacy of treatment 130
6.4.3 POST-TREATMENT SURVEILLANCE & FOLLOW-UP 131
6.4.3.1 AI algorithms to identify subtle patterns in data, allowing for early detection of potential issues 131
7 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA 133
7.1 INTRODUCTION 134
7.2 ONCOLOGY 134
7.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS 134
7.3 RARE DISEASES 136
7.3.1 COMBATING CHALLENGING THERAPEUTICS DUE TO COMPLEX AND HETEROGENEOUS NATURE OF RARE DISEASES 136
7.4 INFECTIOUS DISEASES 137
7.4.1 NEED FOR INNOVATION IN INFECTIOUS DISEASE TREATMENT, ESPECIALLY AFTER IMPACT OF COVID-19 137
7.5 NEUROLOGY 139
7.5.1 SHORTAGE AND COMPLEXITY OF NEURODEGENERATIVE DISEASES 139
7.6 CARDIOLOGY 141
7.6.1 WIDE RANGE AND INCIDENCE OF CARDIOVASCULAR DISEASES 141
7.7 HEMATOLOGY 142
7.7.1 AI-DRIVEN ALGORITHMS TO ANALYZE BLOOD SAMPLES, IMAGING DATA,
AND GENOMIC PROFILES TO DETECT ABNORMALITIES 142
7.8 OTHER THERAPEUTIC AREAS 143
8 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT 145
8.1 INTRODUCTION 146
8.2 SOFTWARE 146
8.2.1 SCALABILITY AND FLEXIBILITY OF AI SOFTWARE TO ENHANCE EFFICIENCY OF CLINICAL WORKFLOWS 146
8.3 SERVICES 148
8.3.1 NEED FOR EXPERT ASSISTANCE AMONG HEALTHCARE ORGANIZATIONS IN ADOPTING AND OPTIMIZING AI TECHNOLOGIES 148
9 AI IN PRECISION MEDICINE MARKET, BY TOOL 150
9.1 INTRODUCTION 151
9.2 MACHINE LEARNING 151
9.2.1 DEEP LEARNING 153
9.2.1.1 Convolutional neural networks 154
9.2.1.1.1 Interpreting complex biological data to enable personalizing healthcare 154
9.2.1.2 Recurrent neural networks (RNNs) 155
9.2.1.2.1 Optimizing clinical data to model patient trajectories by analyzing longitudinal data 155
9.2.1.3 Generative adversarial networks (GANs) 156
9.2.1.3.1 GAN to focus on new molecules and biological datasets 156
9.2.1.4 Graph neural networks (GNNs) 157
9.2.1.4.1 Predicting drug-drug interactions to optimize personalized treatment 157
9.2.1.5 Other deep learning tools 158
9.2.2 SUPERVISED MACHINE LEARNING 158
9.2.3 REINFORCEMENT MACHINE LEARNING 159
9.2.4 UNSUPERVISED MACHINE LEARNING 160
9.2.5 OTHER MACHINE LEARNING TOOLS 161
9.3 NATURAL LANGUAGE PROCESSING 162
9.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO BE INTERPRETED 162
9.4 CONTEXT-AWARE PROCESSING & COMPUTING 163
9.4.1 TAILORING PATIENT CARE IN REAL TIME TO ENHANCE PRECISION MEDICINE 163
9.5 COMPUTER VISION 164
9.5.1 INCREASE IN USE OF IMAGING BIOMARKERS TO SUPPORT SURGICAL PRECISION 164
9.6 IMAGE ANALYSIS 165
9.6.1 HARNESSING MACHINE LEARNING TO AUTOMATE TECHNIQUES SUCH AS QUANTITATIVE IMAGING AND RADIOMICS 165
9.7 OTHER TOOLS 166
10 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT 168
10.1 INTRODUCTION 169
10.2 CLOUD-BASED MODEL 169
10.2.1 RESEARCH COLLABORATION AND COST-EFFICIENCY OF CLOUD DEPLOYMENT 169
10.3 ON-PREMISE MODEL 171
10.3.1 EASIER TO SECURE PATIENT DATA AND ENSURE COMPLIANCE IN ON-PREMISE AI-DRIVEN PRECISION MEDICINE 171
10.4 HYBRID MODEL 172
10.4.1 HYBRID MODELS TO ENHANCE FLEXIBILITY AND SECURITY 172
11 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER 174
11.1 INTRODUCTION 175
11.2 HEALTHCARE PROVIDERS 175
11.2.1 REVOLUTIONIZING PATIENT CARE AND TREATMENT DELIVERY THROUGH ADVANCED TECHNOLOGIES 175
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 176
11.3.1 DRIVING DRUG DEVELOPMENT EFFICIENCY TO DESIGN ADAPTIVE TRIAL PROTOCOLS AND OPTIMIZE TREATMENT 176
11.4 MEDICAL DEVICE & EQUIPMENT COMPANIES 177
11.4.1 INTEGRATION OF AI IN MEDICAL DEVICES TO ENHANCE PRECISION AND PERSONALIZED HEALTHCARE 177
11.5 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS 178
11.5.1 AI IN ACADEMIC INSTITUTES AND PUBLIC SECTOR COLLABORATIONS TO ACCELERATE INNOVATION AND RESEARCH 178
11.6 OTHER END USERS 179
12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION 181
12.1 INTRODUCTION 182
12.2 NORTH AMERICA 182
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 183
12.2.2 US 187
12.2.2.1 US to dominate North American market with advanced regulatory system 187
12.2.3 CANADA 190
12.2.3.1 Emergence of new AI-based startups and high health expenditure 190
12.3 EUROPE 194
12.3.1 EUROPE: MACROECONOMIC OUTLOOK 194
12.3.2 UK 198
12.3.2.1 Favorable government R&D investment and collaborations focused on drug discovery 198
12.3.3 GERMANY 201
12.3.3.1 Growing R&D investment by pharma and biotech companies 201
12.3.4 FRANCE 204
12.3.4.1 Strong government support through investments in initiatives 204
12.3.5 ITALY 208
12.3.5.1 Government Initiatives addressing local healthcare challenges through studies aimed at broader precision medicine strategies 208
12.3.6 SPAIN 211
12.3.6.1 High investments by pharmaceutical companies 211
12.3.7 REST OF EUROPE 214
12.4 ASIA PACIFIC 217
12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 217
12.4.2 JAPAN 222
12.4.2.1 High investment in R&D and government initiatives focused on treatment outcomes 222
12.4.3 CHINA 226
12.4.3.1 Government funding to advance data analysis and international collaborations to develop targeted therapies 226
12.4.4 INDIA 229
12.4.4.1 High growth of pharmaceutical and medical device industries 229
12.4.5 REST OF ASIA PACIFIC 233
12.5 LATIN AMERICA 236
12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 236
12.5.2 BRAZIL 240
12.5.2.1 Increase in governmental support through initiatives such as Brazilian Artificial Intelligence Plan 240
12.5.3 MEXICO 243
12.5.3.1 High potential to become leader in terms of readiness in technology 243
12.5.4 REST OF LATIN AMERICA 246
12.6 MIDDLE EAST & AFRICA 249
12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 249
12.6.2 GCC COUNTRIES 253
12.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure 253
12.6.3 REST OF MIDDLE EAST & AFRICA 257
13 COMPETITIVE LANDSCAPE 261
13.1 INTRODUCTION 261
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 261
13.3 REVENUE ANALYSIS, 2019–2023 264
13.4 MARKET SHARE ANALYSIS, 2023 265
13.4.1 RANKING OF KEY MARKET PLAYERS 267
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 268
13.5.1 STARS 268
13.5.2 EMERGING LEADERS 268
13.5.3 PERVASIVE PLAYERS 268
13.5.4 PARTICIPANTS 268
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 270
13.5.5.1 Company footprint 270
13.5.5.2 Therapeutic area footprint 271
13.5.5.3 End user footprint 272
13.5.5.4 Component footprint 273
13.5.5.5 Deployment footprint 274
13.5.5.6 Region footprint 275
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 276
13.6.1 PROGRESSIVE COMPANIES 276
13.6.2 RESPONSIVE COMPANIES 276
13.6.3 DYNAMIC COMPANIES 276
13.6.4 STARTING BLOCKS 276
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 278
13.6.5.1 Detailed list of key startup/SME players 278
13.6.5.2 Competitive benchmarking of key emerging players/startups, by region 279
13.7 COMPANY VALUATION AND FINANCIAL METRICS 279
13.7.1 COMPANY VALUATION 279
13.7.2 FINANCIAL METRICS 280
13.8 BRAND/PRODUCT COMPARISON 281
13.9 COMPETITIVE SCENARIO 282
13.9.1 PRODUCT LAUNCHES 282
13.9.2 DEALS 283
13.9.3 EXPANSIONS 285
13.9.4 OTHER DEVELOPMENTS 286
14 COMPANY PROFILES 287
14.1 KEY PLAYERS 287
14.1.1 NVIDIA CORPORATION 287
14.1.1.1 Business overview 287
14.1.1.2 Products/Services/Solutions offered 289
14.1.1.3 Recent developments 289
14.1.1.3.1 Product launches 289
14.1.1.3.2 Deals 291
14.1.1.4 MnM view 295
14.1.1.4.1 Right to win 295
14.1.1.4.2 Strategic choices 295
14.1.1.4.3 Weaknesses & competitive threats 295
14.1.2 EXSCIENTIA 296
14.1.2.1 Business overview 296
14.1.2.2 Products/Services/Solutions offered 297
14.1.2.3 Recent developments 298
14.1.2.3.1 Product launches 298
14.1.2.3.2 Deals 298
14.1.2.3.3 Expansions 303
14.1.2.3.4 Other developments 304
14.1.2.4 MnM view 305
14.1.2.4.1 Right to win 305
14.1.2.4.2 Strategic choices 305
14.1.2.4.3 Weaknesses and competitive threats 306
14.1.3 GOOGLE 307
14.1.3.1 Business overview 307
14.1.3.2 Products/Services/Solutions offered 309
14.1.3.3 Recent developments 309
14.1.3.3.1 Product launches 309
14.1.3.3.2 Deals 310
14.1.3.3.3 Expansions 311
14.1.3.4 MnM view 311
14.1.3.4.1 Right to win 311
14.1.3.4.2 Strategic choices 311
14.1.3.4.3 Weaknesses and competitive threats 312
14.1.4 ILLUMINA, INC. 313
14.1.4.1 Business overview 313
14.1.4.2 Products/Services/Solutions offered 314
14.1.4.3 Recent developments 315
14.1.4.3.1 Product launches 315
14.1.4.3.2 Deals 316
14.1.4.4 MnM view 317
14.1.4.4.1 Right to win 317
14.1.4.4.2 Strategic choices 317
14.1.4.4.3 Weaknesses and competitive threats 317
14.1.5 TEMPUS AI, INC. 318
14.1.5.1 Business overview 318
14.1.5.2 Products/Services/Solutions offered 318
14.1.5.3 Recent developments 319
14.1.5.3.1 Product launches 319
14.1.5.3.2 Deals 320
14.1.5.3.3 Expansions 323
14.1.5.3.4 Other developments 324
14.1.5.4 MnM view 324
14.1.5.4.1 Right to win 324
14.1.5.4.2 Strategic choices 324
14.1.5.4.3 Weaknesses and competitive threats 324
14.1.6 BENEVOLENTAI 325
14.1.6.1 Business overview 325
14.1.6.2 Products/Services/Solutions offered 326
14.1.6.3 Recent developments 326
14.1.6.3.1 Deals 326
14.1.7 MICROSOFT CORPORATION 329
14.1.7.1 Business overview 329
14.1.7.2 Products/Services/Solutions offered 331
14.1.7.3 Recent developments 331
14.1.7.3.1 Deals 331
14.1.8 IBM 334
14.1.8.1 Business overview 334
14.1.8.2 Products/Services/Solutions offered 336
14.1.8.3 Recent developments 336
14.1.8.3.1 Deals 336
14.1.9 GE HEALTHCARE 337
14.1.9.1 Business overview 337
14.1.9.2 Products/Services/Solutions offered 338
14.1.9.3 Recent developments 339
14.1.9.3.1 Product launches 339
14.1.9.3.2 Deals 340
14.1.9.3.3 Other developments 341
14.1.10 DEEP GENOMICS 342
14.1.10.1 Business overview 342
14.1.10.2 Products/Services/Solutions offered 342
14.1.10.3 Recent developments 343
14.1.10.3.1 Product launches 343
14.1.10.3.2 Deals 343
14.1.10.3.3 Other developments 343
14.1.11 SIEMENS HEALTHINEERS AG 344
14.1.11.1 Business overview 344
14.1.11.2 Products/Solutions/Services offered 345
14.1.11.3 Recent developments 346
14.1.11.3.1 Deals 346
14.1.12 BIOXCEL THERAPEUTICS, INC. 347
14.1.12.1 Business overview 347
14.1.12.2 Products/Solutions/Services offered 347
14.1.12.3 Recent developments 348
14.1.12.3.1 Deals 348
14.1.12.3.2 Other developments 348
14.1.13 INSILICO MEDICINE 349
14.1.13.1 Business overview 349
14.1.13.2 Products/Services/Solutions offered 350
14.1.13.3 Recent developments 350
14.1.13.3.1 Product launches 350
14.1.13.3.2 Deals 352
14.1.13.3.3 Other developments 356
14.1.14 PATHAI, INC. 358
14.1.14.1 Business overview 358
14.1.14.2 Products/Services/Solutions offered 359
14.1.14.3 Recent developments 360
14.1.14.3.1 Product launches 360
14.1.14.3.2 Deals 362
14.1.14.3.3 Other developments 364
14.1.15 VERGE GENOMICS 365
14.1.15.1 Business overview 365
14.1.15.2 Products/Services/Solutions offered 365
14.1.15.3 Recent developments 366
14.1.15.3.1 Deals 366
14.1.16 GUARDANT HEALTH, INC. 367
14.1.16.1 Business overview 367
14.1.16.2 Products/Services/Solutions offered 368
14.1.16.3 Recent developments 369
14.1.16.3.1 Product launches 369
14.1.16.3.2 Deals 370
14.1.16.3.3 Other developments 372
14.1.17 GRAIL, INC. 374
14.1.17.1 Business overview 374
14.1.17.2 Products/Services/Solutions offered 374
14.1.17.3 Recent developments 375
14.1.17.3.1 Deals 375
14.1.18 FOUNDATION MEDICINE, INC. 377
14.1.18.1 Business overview 377
14.1.18.2 Products/Services/Solutions offered 377
14.1.18.3 Recent developments 378
14.1.18.3.1 Deals 378
14.1.18.3.2 Other developments 380
14.1.19 PROSCIA INC. 382
14.1.19.1 Business overview 382
14.1.19.2 Products/Services/Solutions offered 382
14.1.19.3 Recent developments 383
14.1.19.3.1 Product launches 383
14.1.19.3.2 Deals 383
14.1.19.3.3 Other developments 384
14.1.20 FLATIRON HEALTH 385
14.1.20.1 Business overview 385
14.1.20.2 Products/Services/Solutions offered 385
14.1.20.3 Recent developments 386
14.1.20.3.1 Deals 386
14.1.20.3.2 Other developments 387
14.2 OTHER PLAYERS 388
14.2.1 PREDICTIVE ONCOLOGY 388
14.2.2 PAIGE AI, INC. 389
14.2.3 DENSITAS INC. 390
14.2.4 ZEPHYR AI, INC. 391
14.2.5 NUCLEAI, INC. 392
15 APPENDIX 393
15.1 DISCUSSION GUIDE 393
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 399
15.3 CUSTOMIZATION OPTIONS 401
15.4 RELATED REPORTS 401
15.5 AUTHOR DETAILS 402
LIST OF TABLES
TABLE 1 AI IN PRECISION MEDICINE MARKET: INCLUSIONS & EXCLUSIONS 34
TABLE 2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET DYNAMICS: IMPACT ANALYSIS 62
TABLE 3 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021–2024 65
TABLE 4 BIGGEST HEALTHCARE SECURITY BREACHES, 2023 70
TABLE 5 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM 78
TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 88
TABLE 12 NORTH AMERICA: REGULATORY SCENARIO 89
TABLE 13 EUROPE: REGULATORY SCENARIO 90
TABLE 14 ASIA PACIFIC: REGULATORY SCENARIO 91
TABLE 15 MIDDLE EAST & AFRICA: REGULATORY SCENARIO 92
TABLE 16 LATIN AMERICA: REGULATORY SCENARIO 92
TABLE 17 INDICATIVE PRICING FOR KEY PLAYERS, 2023 (USD) 93
TABLE 18 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION, 2022–2024 (USD) 94
TABLE 19 AI IN PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 96
TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE 98
TABLE 21 AI IN PRECISION MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS 99
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS 102
TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 103
TABLE 24 UNMET NEEDS IN AI IN PRECISION MEDICINE MARKET 104
TABLE 25 END-USER EXPECTATIONS IN AI IN PRECISION MEDICINE MARKET 105
TABLE 26 KEY CONFERENCES & EVENTS, 2024–2025 106
TABLE 27 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 116
TABLE 28 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY APPLICATION, 2022–2030 (USD MILLION) 116
TABLE 29 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY, BY APPLICATION, 2022–2030 (USD MILLION) 117
TABLE 30 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR UNDERSTANDING DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 118
TABLE 31 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG REPURPOSING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 119
TABLE 32 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DE NOVO DRUG DESIGN, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 120
TABLE 33 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG OPTIMIZATION, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 121
TABLE 34 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SAFETY & TOXICITY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 122
TABLE 35 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLINICAL DEVELOPMENT, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 123
TABLE 36 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DIAGNOSTICS & SCREENING, BY TYPE, 2022–2030 (USD MILLION) 124
TABLE 37 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 125
TABLE 38 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE SCREENING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 126
TABLE 39 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 127
TABLE 40 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE PROGRESSION, STAGING, AND PROGNOSIS, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 128
TABLE 41 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPEUTICS, BY TYPE, 2022–2030 (USD MILLION) 129
TABLE 42 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY SELECTION & PLANNING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 130
TABLE 43 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY MONITORING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 131
TABLE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR POST-TREATMENT SURVEILLANCE & FOLLOW-UP, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 132
TABLE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 134
TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 136
TABLE 47 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 137
TABLE 48 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 139
TABLE 49 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR NEUROLOGY,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 140
TABLE 50 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOLOGY 141
TABLE 51 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CARDIOLOGY,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 142
TABLE 52 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 143
TABLE 53 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 144
TABLE 54 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 146
TABLE 55 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SOFTWARE,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 147
TABLE 56 ARTIFICIAL INTELLIGENCE SERVICES IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 149
TABLE 57 AI IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 151
TABLE 58 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY TYPE,
2022–2030 (USD MILLION) 152
TABLE 59 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 152
TABLE 60 DEEP LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 153
TABLE 61 CONVOLUTIONAL NEURAL NETWORKS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 154
TABLE 62 RECURRENT NEURAL NETWORKS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 155
TABLE 63 GENERATIVE ADVERSARIAL NETWORKS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 156
TABLE 64 GRAPH NEURAL NETWORKS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 157
TABLE 65 OTHER DEEP LEARNING TOOLS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 158
TABLE 66 SUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 159
TABLE 67 REINFORCEMENT LEARNING IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 160
TABLE 68 UNSUPERVISED LEARNING IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 161
TABLE 69 OTHER MACHINE LEARNING TOOLS IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 162
TABLE 70 NATURAL LANGUAGE PROCESSING IN PRECISION MEDICINE MARKET,
BY COUNTRY/REGION, 2022–2030 (USD MILLION) 163
TABLE 71 CONTEXT-AWARE PROCESSING & COMPUTING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 164
TABLE 72 COMPUTER VISION AI IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 165
TABLE 73 IMAGE ANALYSIS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 166
TABLE 74 OTHER AI TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 167
TABLE 75 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 169
TABLE 76 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLOUD-BASED MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 171
TABLE 77 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR ON-PREMISE MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 172
TABLE 78 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HYBRID MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 173
TABLE 79 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 175
TABLE 80 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 176
TABLE 81 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION,
2022–2030 (USD MILLION) 177
TABLE 82 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR MEDICAL DEVICE & EQUIPMENT COMPANIES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 178
TABLE 83 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 179
TABLE 84 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 180
TABLE 85 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION,
2022–2030 (USD MILLION) 182
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 184
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 184
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 185
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 185
TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 186
TABLE 91 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT 2022–2030 (USD MILLION) 186
TABLE 92 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 187
TABLE 93 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 188
TABLE 94 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 188
TABLE 95 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 189
TABLE 96 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL,
2022–2030 (USD MILLION) 189
TABLE 97 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022–2030 (USD MILLION) 189
TABLE 98 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 190
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 191
TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 191
TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 192
TABLE 102 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 192
TABLE 103 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT 2022–2030 (USD MILLION) 193
TABLE 104 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 193
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 195
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 195
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 196
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 196
TABLE 109 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 197
TABLE 110 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 197
TABLE 111 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 198
TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 199
TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 199
TABLE 114 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 200
TABLE 115 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL,
2022–2030 (USD MILLION) 200
TABLE 116 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 200
TABLE 117 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 201
TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 202
TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 202
TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 203
TABLE 121 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 203
TABLE 122 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 204
TABLE 123 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 204
TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 205
TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 205
TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 206
TABLE 127 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 206
TABLE 128 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 207
TABLE 129 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 207
TABLE 130 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 208
TABLE 131 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 209
TABLE 132 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 209
TABLE 133 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 210
TABLE 134 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 210
TABLE 135 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 211
TABLE 136 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 212
TABLE 137 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 212
TABLE 138 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 213
TABLE 139 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 213
TABLE 140 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 213
TABLE 141 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 214
TABLE 142 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 214
TABLE 143 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 215
TABLE 144 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 215
TABLE 145 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 216
TABLE 146 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 216
TABLE 147 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 217
TABLE 148 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COUNTRY, 2022–2030 (USD MILLION) 219
TABLE 149 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 219
TABLE 150 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 220
TABLE 151 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 220
TABLE 152 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 221
TABLE 153 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 221
TABLE 154 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 222
TABLE 155 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 223
TABLE 156 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 223
TABLE 157 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 224
TABLE 158 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 224
TABLE 159 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 225
TABLE 160 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 225
TABLE 161 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 226
TABLE 162 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 227
TABLE 163 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 227
TABLE 164 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 228
TABLE 165 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 228
TABLE 166 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 229
TABLE 167 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 230
TABLE 168 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 230
TABLE 169 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 231
TABLE 170 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 231
TABLE 171 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 232
TABLE 172 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 232
TABLE 173 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 233
TABLE 174 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 234
TABLE 175 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 234
TABLE 176 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 235
TABLE 177 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 235
TABLE 178 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 236
TABLE 179 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY REGION, 2022–2030 (USD MILLION) 237
TABLE 180 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 237
TABLE 181 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 238
TABLE 182 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 238
TABLE 183 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 239
TABLE 184 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 239
TABLE 185 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 240
TABLE 186 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 241
TABLE 187 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 241
TABLE 188 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 242
TABLE 189 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 242
TABLE 190 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 242
TABLE 191 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 243
TABLE 192 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 244
TABLE 193 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 244
TABLE 194 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 245
TABLE 195 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 245
TABLE 196 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 245
TABLE 197 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 246
TABLE 198 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 246
TABLE 199 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 247
TABLE 200 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 247
TABLE 201 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 248
TABLE 202 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 248
TABLE 203 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 249
TABLE 204 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022–2030 (USD MILLION) 250
TABLE 205 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 250
TABLE 206 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 251
TABLE 207 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 251
TABLE 208 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 252
TABLE 209 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 252
TABLE 210 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 253
TABLE 211 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY APPLICATION, 2022–2030 (USD MILLION) 254
TABLE 212 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 254
TABLE 213 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY COMPONENT, 2022–2030 (USD MILLION) 255
TABLE 214 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY TOOL, 2022–2030 (USD MILLION) 255
TABLE 215 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY DEPLOYMENT, 2022–2030 (USD MILLION) 256
TABLE 216 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET,
BY END USER, 2022–2030 (USD MILLION) 256
TABLE 217 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 257
TABLE 218 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 258
TABLE 219 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 258
TABLE 220 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 259
TABLE 221 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 259
TABLE 222 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 260
TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI PRECISION MEDICINE MARKET, JANUARY 2021–OCTOBER 2024 261
TABLE 224 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEGREE OF COMPETITION 265
TABLE 225 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT, 2023 271
TABLE 226 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: END USER FOOTPRINT, 2023 272
TABLE 227 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPONENT FOOTPRINT, 2023 273
TABLE 228 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEPLOYMENT FOOTPRINT, 2023 274
TABLE 229 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET:
REGION FOOTPRINT, 2023 275
TABLE 230 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS, 2023 278
TABLE 231 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION, 2023 279
TABLE 232 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 282
TABLE 233 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEALS, J ANUARY 2021–OCTOBER 2024 283
TABLE 234 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 285
TABLE 235 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 286
TABLE 236 NVIDIA CORPORATION: COMPANY OVERVIEW 287
TABLE 237 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 289
TABLE 238 NVIDIA CORPORATION: PRODUCT LAUNCHES 289
TABLE 239 NVIDIA CORPORATION: DEALS 291
TABLE 240 EXSCIENTIA: COMPANY OVERVIEW 296
TABLE 241 EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 297
TABLE 242 EXSCIENTIA: PRODUCT LAUNCHES 298
TABLE 243 EXSCIENTIA: DEALS 298
TABLE 244 EXSCIENTIA: EXPANSIONS 303
TABLE 245 EXSCIENTIA: OTHER DEVELOPMENTS 304
TABLE 246 GOOGLE: COMPANY OVERVIEW 307
TABLE 247 GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 309
TABLE 248 GOOGLE: PRODUCT LAUNCHES 309
TABLE 249 GOOGLE: DEALS 310
TABLE 250 GOOGLE: EXPANSIONS 311
TABLE 251 ILLUMINA, INC.: COMPANY OVERVIEW 313
TABLE 252 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 314
TABLE 253 ILLUMINA, INC.: PRODUCT LAUNCHES 315
TABLE 254 ILLUMINA, INC.: DEALS 316
TABLE 255 TEMPUS: COMPANY OVERVIEW 318
TABLE 256 TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 318
TABLE 257 TEMPUS: PRODUCT LAUNCHES 319
TABLE 258 TEMPUS: DEALS 320
TABLE 259 TEMPUS: EXPANSIONS 323
TABLE 260 TEMPUS: OTHER DEVELOPMENTS 324
TABLE 261 BENEVOLENTAI: COMPANY OVERVIEW 325
TABLE 262 BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED 326
TABLE 263 BENEVOLENTAI: DEALS 326
TABLE 264 MICROSOFT CORPORATION: COMPANY OVERVIEW 329
TABLE 265 MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 331
TABLE 266 MICROSOFT CORPORATION: DEALS 331
TABLE 267 IBM: COMPANY OVERVIEW 334
TABLE 268 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED 336
TABLE 269 IBM: DEALS 336
TABLE 270 GE HEALTHCARE: COMPANY OVERVIEW 337
TABLE 271 GE HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 338
TABLE 272 GE HEALTHCARE: PRODUCT LAUNCHES 339
TABLE 273 GE HEALTHCARE: DEALS 340
TABLE 274 GE HEALTHCARE: OTHER DEVELOPMENTS 341
TABLE 275 DEEP GENOMICS: COMPANY OVERVIEW 342
TABLE 276 DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 342
TABLE 277 DEEP GENOMICS: PRODUCT LAUNCHES 343
TABLE 278 DEEP GENOMICS: DEALS 343
TABLE 279 DEEP GENOMICS: OTHER DEVELOPMENTS 343
TABLE 280 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 344
TABLE 281 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 345
TABLE 282 SIEMENS HEALTHINEERS AG: DEALS 346
TABLE 283 BIOXCEL THERAPEUTICS, INC.: COMPANY OVERVIEW 347
TABLE 284 BIOXCEL THERAPEUTICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 347
TABLE 285 BIOXCEL THERAPEUTICS, INC.: DEALS 348
TABLE 286 BIOXCEL THERAPEUTICS, INC.: OTHER DEVELOPMENTS 348
TABLE 287 INSILICO MEDICINE: COMPANY OVERVIEW 349
TABLE 288 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 350
TABLE 289 INSILICO MEDICINE: PRODUCT LAUNCHES 350
TABLE 290 INSILICO MEDICINE: DEALS 352
TABLE 291 INSILICO MEDICINE: OTHER DEVELOPMENTS 356
TABLE 292 PATHAI, INC.: COMPANY OVERVIEW 358
TABLE 293 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 359
TABLE 294 PATHAI, INC.: PRODUCT LAUNCHES 360
TABLE 295 PATHAI, INC.: DEALS 362
TABLE 296 PATHAI, INC.: OTHER DEVELOPMENTS 364
TABLE 297 VERGE GENOMICS: COMPANY OVERVIEW 365
TABLE 298 VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 365
TABLE 299 VERGE GENOMICS: DEALS 366
TABLE 300 GUARDANT HEALTH, INC.: COMPANY OVERVIEW 367
TABLE 301 GUARDANT HEALTH, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 368
TABLE 302 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES 369
TABLE 303 GUARDANT HEALTH, INC.: DEALS 370
TABLE 304 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS 372
TABLE 305 GRAIL, INC.: COMPANY OVERVIEW 374
TABLE 306 GRAIL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 374
TABLE 307 GRAIL, INC.: DEALS 375
TABLE 308 FOUNDATION MEDICINE, INC.: COMPANY OVERVIEW 377
TABLE 309 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 377
TABLE 310 FOUNDATION MEDICINE, INC.: DEALS 378
TABLE 311 FOUNDATION MEDICINE, INC.: OTHER DEVELOPMENTS 380
TABLE 312 PROSCIA INC.: COMPANY OVERVIEW 382
TABLE 313 PROSCIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 382
TABLE 314 PROSCIA INC.: PRODUCT LAUNCHES 383
TABLE 315 PROSCIA INC.: DEALS 383
TABLE 316 PROSCIA INC.: OTHER DEVELOPMENTS 384
TABLE 317 FLATIRON HEALTH: COMPANY OVERVIEW 385
TABLE 318 FLATIRON HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 385
TABLE 319 FLATIRON HEALTH: DEALS 386
TABLE 320 FLATIRON HEALTH: OTHER DEVELOPMENTS 387
TABLE 321 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 388
TABLE 322 PAIGE AI, INC.: COMPANY OVERVIEW 389
TABLE 323 DENSITAS INC.: COMPANY OVERVIEW 390
TABLE 324 ZEPHYR AI, INC.: COMPANY OVERVIEW 391
TABLE 325 NUCLEAI, INC.: COMPANY OVERVIEW 392
LIST OF FIGURES
FIGURE 1 AI IN PRECISION MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE 33
FIGURE 2 STUDY YEARS CONSIDERED 36
FIGURE 3 RESEARCH DESIGN 38
FIGURE 4 PRIMARY SOURCES 41
FIGURE 5 INSIGHTS FROM PRIMARY EXPERTS 43
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION 43
FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 8 TOP-DOWN APPROACH 45
FIGURE 9 CAGR PROJECTIONS, BY MARKET DYNAMIC, 2024–2030 46
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47
FIGURE 11 DATA TRIANGULATION 48
FIGURE 12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 51
FIGURE 13 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2024 VS. 2030 (USD MILLION) 52
FIGURE 14 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2024 VS. 2030 (USD MILLION) 52
FIGURE 15 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL,
2024 VS. 2030 (USD MILLION) 53
FIGURE 16 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2024 VS. 2030 (USD MILLION) 54
FIGURE 17 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER,
2024 VS. 2030 (USD MILLION) 54
FIGURE 18 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHICAL SNAPSHOT 55
FIGURE 19 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 57
FIGURE 20 NORTH AMERICA TO DOMINATE AI IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD 58
FIGURE 21 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 59
FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 60
FIGURE 24 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
FIGURE 25 APPROVAL RATE OF PERSONALIZED MEDICINES BY US FDA, 2015–2023 67
FIGURE 26 HEALTH SECURITY BREACHES, 2009–2023 68
FIGURE 27 INDIVIDUALS AFFECTED BY HEALTHCARE SECURITY BREACHES,
2009–2023 (MILLION) 69
FIGURE 28 USE CASES FOR PREDICTIVE ANALYTICS IN HEALTHCARE 72
FIGURE 29 REVENUE SHIFT IN AI IN PRECISION MEDICINE MARKET 75
FIGURE 30 AI IN PRECISION MEDICINE MARKET: ECOSYSTEM ANALYSIS 77
FIGURE 31 AI IN PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS, 2023 79
FIGURE 32 AI IN PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 95
FIGURE 33 JURISDICTION ANALYSIS: TOP PATENT APPLICANT COUNTRIES, JANUARY 2015–NOVEMBER 2024 98
FIGURE 34 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET, JANUARY 2015–
NOVEMBER 2024 99
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 102
FIGURE 36 KEY BUYING CRITERIA FOR END USERS 103
FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING AI IN PRECISION MEDICINE ACROSS INDUSTRIES 111
FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 113
FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT 183
FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT 218
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2019–2023 (USD MILLION) 264
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 265
FIGURE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: RANKING OF KEY PLAYERS, 2023 267
FIGURE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 269
FIGURE 46 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY FOOTPRINT, 2023 270
FIGURE 47 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 277
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 279
FIGURE 49 EV/EBITDA OF KEY VENDORS, 2024 280
FIGURE 50 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 281
FIGURE 51 NVIDIA CORPORATION: COMPANY SNAPSHOT 288
FIGURE 52 EXSCIENTIA: COMPANY SNAPSHOT 297
FIGURE 53 GOOGLE: COMPANY SNAPSHOT 308
FIGURE 54 ILLUMINA, INC.: COMPANY SNAPSHOT 314
FIGURE 55 BENEVOLENTAI: COMPANY SNAPSHOT 325
FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT 330
FIGURE 57 IBM: COMPANY SNAPSHOT 335
FIGURE 58 GE HEALTHCARE: COMPANY SNAPSHOT 338
FIGURE 59 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 345
FIGURE 60 GUARDANT HEALTH: COMPANY SNAPSHOT 368
